Commodore Capital LP Arrowhead Pharmaceuticals, Inc. Transaction History

Commodore Capital LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$25.16 - $41.38 $880,600 - $1.45 Million	35,000 Added 6.09%	610,000 $21.8 Million
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $2.67 Million - $4.35 Million	112,889 Added 24.43%	575,000 $14.6 Million
Q4 2022 Feb 14, 2023	BUY	$28.0 - $40.56 $1.62 Million - $2.35 Million	58,033 Added 14.36%	462,111 $18.7 Million
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $2.71 Million - $4.42 Million	91,545 Added 29.29%	404,078 $13.4 Million
Q2 2022 Aug 15, 2022	BUY	$27.79 - $50.61 $8.69 Million - $15.8 Million	312,533 New	312,533 $11 Million

295

91.1M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.96B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

Stay updated on Commodore Capital LP with notifications on news.